CALC
CalciMedica, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$10.25M
P/E Ratio
—
EPS
$-1.97
Beta
1.09
52W High
$7.20
52W Low
$0.46
50-Day MA
$0.94
200-Day MA
$2.86
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About CalciMedica, Inc. Common Stock
CalciMedica, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel therapies for acute and chronic conditions related to calcium-dependent pathways, particularly with its lead candidate, CM4620, aimed at addressing severe muscle cramps in sickle cell disease. The company utilizes a proprietary technology platform to create innovative calcium modulators and has assembled a strong pipeline bolstered by a veteran management team and strategic collaborations to accelerate clinical development. With its dedication to addressing critical unmet medical needs and transforming treatment landscapes, CalciMedica represents a unique and promising investment opportunity within the biopharmaceutical sector.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-23.07M |
| Operating Margin | 0.00% |
| Return on Equity | -761.00% |
| Return on Assets | -86.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.43 |
| Price-to-Book | 7.13 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.26 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $15.74M |
| Float | $9.00M |
| % Insiders | 21.61% |
| % Institutions | 43.48% |
Analyst Ratings
Consensus ($10.33 target)
3
Buy1
HoldData last updated: 4/10/2026